ZAS Ventures Backs Gamow Tech to Boost AI-Powered IVF Treatment
Gamow Tech’s AI system for assessing egg-cell health aims to make IVF more effective and affordable, positioning a Ukrainian-founded team for global scale.
KYIV, Ukraine — 20 October 2025
Gamow Tech, a Ukrainian-founded medtech startup developing artificial intelligence tools to improve in vitro fertilization (IVF) success rates, has secured investment from ZAS Ventures at a valuation of €2.4 million, according to the fund. The capital will support clinical validation, preparation for the EU’s Conformité Européenne (CE) mark certification, and international rollout.
The startup is developing ReSpindle, software that uses computer vision to analyze human oocytes and detect chromosomal abnormalities — a leading cause of age-related infertility. The technology enables embryologists to assess egg-cell viability in real time without invasive procedures and at a fraction of the cost of traditional genetic testing.
In a post announcing the company’s exit from stealth mode, co-founder Max Slyzkouh wrote that Gamow Tech was founded “in the Netherlands” with Kostiantyn Hnennyi and Pavlo Mazur and has since partnered with assisted-reproduction networks representing “more than 31,000 treatments annually.” He added: “this month our model reached MVP-level accuracy, doubling the chances of identifying healthy egg cells, which is priceless for women patients of advanced maternal age.”
ZAS Ventures, founded in 2023 by investor Andrew Zinchuk, focuses on early-stage Ukrainian startups in artificial intelligence, medtech, and SaaS. The firm said its investment in Gamow Tech reflects its strategy to back deep-tech founders addressing global challenges in women’s health and reproductive medicine. The fund has now backed 17 startups with international ambitions.
Gamow Tech has also signed nine R&D agreements with leading IVF centers representing more than 1 percent of the global assisted-reproductive-technology market.
The founding team includes embryologist Pavlo Mazur — featured in Netflix’s Unnatural Selection — biophysicist and former Forbes analyst Kostiantyn Hnennyi, and deep-tech entrepreneur Max Slyzkouh. David Mayboroda, formerly of Reface, serves as chief technology officer.
The global IVF market is estimated at €26 billion, underscoring the scale of opportunity for technologies like ReSpindle that could make advanced fertility screening more accessible and affordable worldwide.
